Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

31.10
-0.0200-0.06%
Post-market: 31.510.4100+1.32%16:27 EDT
Volume:754.99K
Turnover:23.73M
Market Cap:2.17B
PE:-10.39
High:31.96
Open:31.14
Low:31.09
Close:31.12
52wk High:43.25
52wk Low:20.65
Shares:69.86M
Float Shares:44.23M
Volume Ratio:1.20
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9943
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:6.45
PE(LYR):-8.92

Loading ...

Sweden's Biovica Q1 Sales Rise on Pharma Services Growth

Reuters
·
Sep 09

Pharvaris President Lu Peng Disposes of USD 610,134 Common Shares

Reuters
·
Sep 09

Pharvaris (PHVS) Gets a Buy from Leerink Partners

TIPRANKS
·
Sep 09

Pharvaris price target raised to $65 from $52 at Jones

TIPRANKS
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Pharvaris (PHVS) and Zimmer Biomet Holdings (ZBH)

TIPRANKS
·
Sep 09

Pharvaris N.v. : RBC Raises Target Price to $62 from $52

THOMSON REUTERS
·
Sep 09

Pharvaris: Kbc Securities Raises Target Price to $49 from $39; Rating Buy

THOMSON REUTERS
·
Sep 09

Pharvaris price target raised to $75 from $50 at Oppenheimer

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Top Midday Gainers

MT Newswires Live
·
Sep 09

Pharvaris Shares Rise on Positive Results for Hereditary Angioedema Trial

Dow Jones
·
Sep 08

Wedbush Adjusts Pharvaris Price Target to $50 From $42, Maintains Outperform Rating

MT Newswires Live
·
Sep 08

Pharvaris rises 16.7%

TIPRANKS
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Shares of Pharvaris up 14% After Co's Genetic Disorder Drug Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Sep 08

Pharvaris Price Target Maintained with a $42.00/Share by Wedbush

Dow Jones
·
Sep 08

Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones

TIPRANKS
·
Sep 08

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Rising Oil Prices

MT Newswires Live
·
Sep 08

Pharvaris Gains After Genetic Disorder Drug Meets Late-Stage Trial Goal

Reuters
·
Sep 08

Shares of Pharvaris up 26.5% Premarket After Co's Genetic Disorder Drug Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Sep 08